Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.28 +10.1%	$1.95	$1.33 ▼ $3.58	$97.52M	0.74	99,132 shs	87,068 shs
BYSI BeyondSpring	$1.76 +2.3%	$2.25	$0.98 ▼ $3.44	$69.37M	0.26	26,716 shs	42,162 shs
EXOZ eXoZymes	$9.31 -4.8%	$10.14	$8.50 ▼ $23.99	$82.07M	N/A	3,258 shs	7,776 shs
NICXF Nicox	$0.30	$0.28	$0.25 ▼ $0.30	$20.67M	0.33	N/A	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	+5.61%	+25.45%	+7.25%	+27.38%	-20.08%
BYSI BeyondSpring	-1.71%	-14.00%	-8.51%	+2.38%	-11.79%
EXOZ eXoZymes	0.00%	-2.10%	+3.38%	-33.01%	+977,999,900.00%
NICXF Nicox	0.00%	0.00%	0.00%	+20.00%	-31.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	2.9721 of 5 stars	3.5	5.0	0.0	0.0	2.4	1.7	0.0
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NICXF Nicox	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$7.00	206.21% Upside
BYSI BeyondSpring	0.00	N/A	N/A	N/A
EXOZ eXoZymes	0.00	N/A	N/A	N/A
NICXF Nicox	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NICXF, BYSI, EXOZ, and ADAG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/6/2025	ADAG Adagene	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	ADAG Adagene	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	1,076.93	N/A	N/A	$0.80 per share	2.86
BYSI BeyondSpring	$1.75M	40.56	N/A	N/A	($0.44) per share	-4.00
EXOZ eXoZymes	$70K	1,115.87	N/A	N/A	$0.86 per share	10.83
NICXF Nicox	$5.52M	3.75	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	-$11.12M	N/A	∞	N/A	N/A	N/A	N/A	11/6/2025 (Estimated)
EXOZ eXoZymes	-$5.86M	N/A	∞	N/A	N/A	-134.50%	-81.63%	N/A
NICXF Nicox	-$29.25M	N/A	∞	N/A	N/A	N/A	N/A	10/16/2025 (Estimated)

Latest NICXF, BYSI, EXOZ, and ADAG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	BYSI BeyondSpring	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/12/2025	Q2 2025	EXOZ eXoZymes	N/A	-$0.28	N/A	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
NICXF Nicox	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.29	2.30
BYSI BeyondSpring	N/A	2.19	2.19
EXOZ eXoZymes	0.01	6.19	6.19
NICXF Nicox	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
BYSI BeyondSpring	40.29%
EXOZ eXoZymes	N/A
NICXF Nicox	N/A

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
BYSI BeyondSpring	29.31%
EXOZ eXoZymes	72.41%
NICXF Nicox	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
BYSI BeyondSpring	80	40.33 million	28.51 million	Optionable
EXOZ eXoZymes	29	8.39 million	2.31 million	N/A
NICXF Nicox	28	68.92 million	N/A	Not Optionable

NICXF, BYSI, EXOZ, and ADAG Headlines

Recent News About These Companies

Positive Outlook for Nicox SA Driven by Successful NCX 470 Trial and Strategic Partnerships

August 21 at 12:50 PM | tipranks.com

Nicox SA (OTCMKTS:NICXF) Sees Large Increase in Short Interest

August 16, 2025 | americanbankingnews.com

Nicox Extends Existing Flexible Equity Financing

August 8, 2025 | uk.finance.yahoo.com

Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

August 5, 2025 | uk.finance.yahoo.com

Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470

July 21, 2025 | ophthalmologytimes.comO

Nicox SA’s Strategic Developments and Promising Trials Justify Buy Rating

July 17, 2025 | tipranks.com

Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories

July 17, 2025 | taiwannews.com.twT

Nicox S.A. (NICXF) Stock Price, Quote, News & Analysis

July 1, 2025 | seekingalpha.com

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension

June 30, 2025 | ophthalmologytimes.comO

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial

June 30, 2025 | manilatimes.netM

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative

June 6, 2025 | santelog.comS

NICOX SA: Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan

May 27, 2025 | finanznachrichten.de

Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan

May 27, 2025 | finance.yahoo.com

Nicox releases results from Whistler phase 3b trial in IOP lowering eye drops

May 15, 2025 | ophthalmologytimes.comO

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial

May 14, 2025 | finance.yahoo.com

NicOx S.A.

May 10, 2025 | barrons.com

Nicox Provides Full Year 2024 Financial Results

April 30, 2025 | finance.yahoo.com

Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial

March 24, 2025 | ophthalmologytimes.comO

NICOX SA: Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

March 19, 2025 | finanznachrichten.de

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

March 19, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NICXF, BYSI, EXOZ, and ADAG Company Descriptions

Adagene NASDAQ:ADAG

$2.28 +0.21 (+10.14%)

Closing price 03:57 PM Eastern

Extended Trading

$2.28 +0.01 (+0.22%)

As of 04:10 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

BeyondSpring NASDAQ:BYSI

$1.76 +0.04 (+2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$1.76 +0.00 (+0.28%)

As of 05:08 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

eXoZymes NASDAQ:EXOZ

$9.31 -0.47 (-4.81%)

As of 04:00 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Nicox OTCMKTS:NICXF

$0.30 0.00 (0.00%)

As of 08/20/2025

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time